News | Women's Health | April 26, 2016

Researchers warn variations in content, readability and understandability could impact patients’ understanding of importance of breast density

breast density notifications, understandability, JAMA study, Nancy R. Kressin

April 26, 2016 — In a study appearing in the April 26 issue of JAMA, researchers examined the content, readability and understandability of dense breast notifications sent to women following screening mammography. The study was conducted by Nancy R. Kressin, Ph.D., of the Veterans Affairs Boston Healthcare System, Boston University School of Medicine and colleagues.

Along with their screening mammogram results, women in nearly half of U.S. states also receive notifications of breast density, a result of legislation intended to assist in making personalized decisions about further action. Dense breasts can mask cancer on mammography (masking bias) and are an independent cancer risk factor, but evidence does not yet indicate whether or what supplemental screening is appropriate. Rather, risk stratification is proposed to determine who may benefit from supplemental screening (e.g., magnetic resonance imaging for women at high risk). The text of dense breast notifications (DBNs) may affect women's ability to understand their message.

Twenty-four states require DBNs as of Jan. l, 2016; the researchers analyzed the characteristics of all but Delaware. They found wide variation in the states’ DBN content. All DBNs mention masking bias, 74 percent mention the association with increased cancer risk and 65 percent mention supplemental screening as an option, advising women to consult their physician. Of 15 DBNs requiring mention of supplemental screening, six (40 percent) inform women that they might benefit from such screening; four mention specific modalities.

Most of the states have readability at the high school level or above (exceeding the recommended readability level [grades 7-8]; about 20 percent of the population reads below a grade 5 level). Only three states' DBN readability level was at the grade 8 level or below; some of the highest readability levels occurred in states with the lowest literacy levels. All DBNs scored poorly on understandability.

“Such problems may create uncertainty for women attempting to make personalized decisions about supplemental screening and may exacerbate disparities in breast cancer screening related to low health literacy,” the authors wrote.

“Efforts should focus on enhancing the understandability of DBNs so that all women are clearly and accurately informed about their density status, its effect on their breast cancer risk, and the harms and benefits of supplemental screening.”

For more information: www.jama.jamanetwork.com

Related Content

News | Breast Imaging

August 19, 2022 — The Christ Hospital Health Network, known for providing the best, most compassionate care for its ...

Time August 19, 2022
arrow
News | Mammography

August 18, 2022 — Intelerad Medical Systems, a leading global provider of enterprise medical imaging solutions, today ...

Time August 18, 2022
arrow
News | Teleradiology

August 17, 2022 — In a study published today in the Journal of General Internal Medicine, researchers at the Icahn ...

Time August 17, 2022
arrow
News | Breast Imaging

August 16, 2022 — Hologic, Inc., a global leader in women’s health, and Grammy award-winning and Oscar-nominated artist ...

Time August 16, 2022
arrow
News | Prostate Cancer

August 16, 2022 — A new study published by University of Kentucky Markey Cancer Center researchers suggests that the ...

Time August 16, 2022
arrow
News | Radiology Education

August 9, 2022 — SBI is pleased to invite all members and nonmembers to submit original abstracts for presentation at ...

Time August 11, 2022
arrow
News | Ultrasound Women's Health

August 10, 2022 — TransMed7, LLC announced that the first clinical cases of the final commercial production version of ...

Time August 10, 2022
arrow
News | Breast Imaging

August 8, 2022 — The U.S. Food and Drug Administration approved Enhertu (fam-trastuzumab-deruxtecan-nxki), an IV ...

Time August 08, 2022
arrow
News | Lung Imaging

August 8, 2022 — Representatives from the Diagnostics Working Group of the IASLC Early Detection and Screening Committee ...

Time August 08, 2022
arrow
News | Lung Imaging

August 8, 2022 — A clinical trial is only as powerful as its participants. For years, researchers have struggled to fill ...

Time August 08, 2022
arrow
Subscribe Now